On June 18, 2026, updated screening guidelines have formally incorporated Multi-Cancer Early Detection (MCED) blood tests into annual wellness checks for adults over 50. By identifying methylation patterns of cell-free DNA (cfDNA) in the bloodstream, MCED assays can detect over 50 types of cancer before physical symptoms or tumors appear.

At Onco Medicine, we support this early-diagnostic paradigm shift. Sourcing early-intervention therapeutics immediately after positive MCED screenings enables clinical teams to treat cancers when they are at their most curable stages.

How MCED Changes Oncology Screening

• High Specificity: The tests exhibit a false-positive rate of less than 1%, minimizing patient anxiety and unnecessary diagnostic follow-ups.
• Origin Mapping: Advanced AI algorithms analyze genomic methylation to predict the organ tissue of cancer origin with over 85% accuracy.
• Silent Tumor Detection: MCED tests identify highly aggressive, historically hard-to-detect cancers such as pancreatic, ovarian, and esophageal cancers in early stages.

Early detection remains the most powerful cure. Moving from reactive cancer treatment to proactive genomic surveillance is saving lives on a global scale. Onco Medicine is proud to provide the specialized oncology portfolio required to support these early-intervention protocols.